Nkarta’s AML Update Disappoints, But New Conditioning Regimen Might Improve Response

 
• By Joseph Haas
  
Natural killer cells
Nkarta reported mixed data for its NK cell therapy in AML • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D